TOKYO, March 13, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results